CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on April 30, 2009
Clinical Journal of the American Society of Nephrology
© 2009 American Society of Nephrology
doi: 10.2215/CJN.05711108
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.05711108v1
4/5/929    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bazzi, C.
Right arrow Articles by D’Amico, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bazzi, C.
Right arrow Articles by D’Amico, G.

Received November 7, 2008
Accepted on March 13, 2009

ORIGINAL ARTICLES

In Crescentic IgA Nephropathy, Fractional Excretion of IgG in Combination with Nephron Loss Is the Best Predictor of Progression and Responsiveness to Immunosuppression

Claudio Bazzi *1, Virginia Rizza {dagger}, Sara Raimondi {ddagger}, Daniela Casellato {sect}, Pietro Napodano {sect}, and Giuseppe D’Amico *

*Fondazione D’Amico per la Ricerca sulle Malattie Renali, {dagger}Biochemical Laboratory, and {sect}Nephrological and Dialysis Unit, San Carlo Borromeo Hospital, and {ddagger}Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy


1 To whom correspondence should be addressed. E-mail: claudio.bazzi{at}alice.it.


  Abstract

Background and objectives: The aim of this study was to evaluate the relationship between proteinuric markers (urinary excretion of IgG, {alpha}2-macroglobulin, {alpha}1-microglobulin) and serum creatinine (sCr), histologic lesions, progression, and immunosuppression responsiveness in crescentic IgA nephropathy.

Design, setting, participants, & measurements: Fractional excretion of IgG (FEIgG) and of {alpha}1-microglobulin and urinary excretion of {alpha}2-macroglobulin were evaluated in 37 patients, 23 treated with steroids and cyclophosphamide. For assessment of the effective tubular load of proteins in surviving nephrons, new markers that take into account not only the absolute excretion value but also nephron loss were obtained dividing proteinuric markers for percentage of nonobsolescent glomeruli (surviving glomeruli [SG]). For each parameter, low- and high-risk groups were defined according to cutoffs with the highest sensitivity and specificity for progression (ESRD/doubling sCr) assessed by receiver operating characteristic analysis; follow up was 60 ± 40 mo.

Results: FEIgG/SG is the most powerful progression predictor: 5 versus 83% in all patients; in treated patients, 0 versus 89%, increased to 0 versus 100% by sCr and FEIgG/SG in combination (low risk: both markers or only one below cutoff (n = 15); high risk: both markers above cutoff (n = 8). The nonprogressors showed at last observation 65% proteinuria reduction and 10% sCr reduction.

Conclusions: In crescentic IgA nephropathy, FEIgG/SG, which evaluates altered size selectivity in relation to nephron loss, is the best progression predictor. In treated patients, progression prediction was increased by FEIgG/SG and sCr in combination. Treatment may be restricted to low-risk patients.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American Society of Nephrology.